Ampio: Ampion reduces all-cause mortality in COVID-19 respiratory distress by nearly 80%
ENGLEWOOD -- Ampio Pharmaceuticals (NYSE American: AMPE) announced positive results in its AP-014 Phase I clinical trial utilizing inhaled Ampion in treating respiratory distress in patients as a... Read More
Wednesday April 28, 2021
Research shows Ampion mimics anti-inflammatory effects of steroids but without adverse effects
ENGLEWOOD -- Ampio Pharmaceuticals (NYSE American: AMPE) announced findings of pre-clinical research demonstrating Ampio's lead drug candidate, Ampion, provides some of the same anti-inflammatory... Read More
Tuesday April 20, 2021
Ampio study: Ampion inhibits key inflammatory pathway in COVID-19 and lupus nephritis
ENGLEWOOD -- Ampio Pharmaceuticals (NYSE American: AMPE) announced results of a pre-clinical study demonstrating Ampion inhibits an important pro-inflammatory pathway in the types of immune cells... Read More
Friday April 9, 2021
Ampio adds new hospitals in trial for inhalation treatment of COVID-19
ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced the addition of two new study sites to further the expansion of its ongoing U.S. Phase I clinical trial for inhalation... Read More
Wednesday February 24, 2021
Ampio announces early positive data in Phase 1 trial of inhaled Ampion in treating COVID-19 distress
ENGLEWOOD -- Ampio Pharmaceuticals, Inc . (NYSE American: AMPE) announced early positive data from its ongoing U.S. Phase I controlled, observer-blinded clinical trial of inhaled Ampion versus... Read More
Tuesday February 2, 2021
Ampio provides update on clinical trials for Ampion treatment of COVID-19
ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced an update on the launch of a new global clinical trial for intravenous treatment of COVID-19 with Ampion and provided updates... Read More
Tuesday January 5, 2021
Ampio gets FDA feedback on proposed modifications to special protocol assessment for Ampion
ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) today announced it received guidance from the U.S Food Drug Administration regarding the impact of COVID-19 on its Phase III clinical... Read More
Wednesday December 30, 2020
Ampion demonstrates safety in COVID patients and initiates global trial for intravenous Ampion
ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced it hascompleted its Phase I clinical trial and has initiated the first steps for a global Phase II clinical trial for... Read More
Friday December 18, 2020
IN Sponsors
Browse
Entrepreneurial by Nature
